Galena Biopharma fka GALE

[JonathanTel]

No worries. Just want to help shed a light on some info for Abstral that most may not be aware of. The "average" person may not understand the full scope of some of these medications, unless in the industry or prior experience.

I truly think that the $2-$2.50 valuation on Abstral may be a little on the conservative side, and this could be why:(My Opnion)

With continued success, Abstral could increase market share and revenue with the addition of smaller/weaker doses. Currently, the "weakest" pill is dosed at 100mcg. As I stated previously, the medication is currently intended for "cancer BT pain". For the non cancer - moderate to severe chronic pain patients, Abstral could make available doses in the 10mcg, 25mcg and 50mcg.

In addition, Abstral is part of and available only through the Risk Evaluation and Mitigation Strategy (REMS)and Transmucosal Immediate Release Fentanyl(TIRF), both which are FDA mandated. both REMS and TIRF have more stringent rules than other commonly prescribed opioids. Below are some links that contain more information the aforementioned programs. In the "overview" PDF, you will see the 3 steps involved with REMS/TIRF meds. The one that stands out to me is that this is not a medication that you can get at every mom and pop or corp RX Shop. Only specific, registered and qualified pharmacies will carry the medication, and even they go through a more stringent verification process once the patient drops off the prescription, even verifying the Doctor is actively enrolled in the TIRF/REMS program.

This will help significantly reduce prescription medication fraud, which is increasingly more and more prevelant within the Pain Management field. This causes hardships on all those involved, patients, pharmacies, and the doctors. Which in turn makes it harder for the legitimate patients to get the appropriate care, as doctors don't want to assume the liability. Having a medication that falls under a strict protocol as Abstral is priceless, as it frees up the Doctors and staff from having to take time away from their practice/patients to go back and forth with the pharmacies via phone calls, emails and or faxes. This will help with wait times, increased Dr patient face time, and create a smoother flow of traffic in the office, cut back on "doctor shopping" / fraudulent scrips, etc.

The reason I think they are light on the valuation for Abstral is it is currently for Breakthrough Pain, not extended release. If they can come up with a way to get Abstral to be an extended release medication, this will increase revenue big time as they will then have an effective combination in house, opposed to the current treatment option which is two have Abstral be used in addition to another "outside" extended release medication. ER meds typically have a sustained release of 12hrs, with the BT meds being used in between for BT pain occurrences.

So as you can see, I think the future potential for Abstral is very good and warrants a higher valuation, if you ask me. Again, thanks for your time. Links below.



https://www.tirfremsaccess.com/TirfUI/rems/patientResources.action

https://www.tirfremsaccess.com/TirfUI/rems/pdf/patient-caregiver-overview.pdf

https://www.tirfremsaccess.com/TirfUI/rems/pdf/ppaf-form.pdf